Article Contents ::
- 1 The Brand Name NITREST Has Generic Salt :: Zolpidem
- 2 NITREST Is From Company Sun Priced :: Rs. 72
- 3 NITREST have Zolpidem is comes under Sub class Sedatives , Hypnotics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Sedatives , Hypnotics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name NITREST Has Generic Salt :: Zolpidem
NITREST Is From Company Sun Priced :: Rs. 72
NITREST have Zolpidem is comes under Sub class Sedatives , Hypnotics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Sedatives , Hypnotics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Drug Dose ::
Short-term management of insomnia Adult: As immediate release tab: 5-10 mg immediately before bedtime. Max: 10 mg/day. As extended release tab: 6.25-12.5 mg immediately before bedtime. Max: 12.5 mg/day. Max duration of treatment: 4 wk including tapering. Elderly: As immediate release tab: 5 mg immediately before bedtime. As extended release tab: 6.25 mg immediately before bedtime. Max duration of treatment: 4 wk including tapering. Renal impairment: No dosage adjustment needed. Hepatic impairment: As immediate release tab: 5 mg immediately before bedtime. As extended release tab: 6.25 mg immediately before bedtime. Max duration of treatment: 4 wk including tapering. Severe: Contraindicated.
Severe hepatic impairment.
Drug Precautions ::
Obstructive sleep apnoea, myasthenia gravis, compromised respiratory function. Patients exhibiting symptoms of depression. History of drug or alcohol abuse. Avoid abrupt withdrawal and rapid dose reduction after prolonged therapy. Re-evaluate if insomnia fail to remit after 7-10 days as this may indicate the presence of underlying psychiatric and/or medical condition. Pregnancy, lactation, childn <18 yr. Patient Counseling Patients should be warned about performing activities involving mental alertness or physical coordination after drug intake. Drug Side Effects ::
Atypical thinking and behaviour, hallucination, nightmare, somnolence, somnambulism, headache, nausea, vomiting, dizziness, vertigo, drowsiness, asthenia, ataxia, rebound insomnia, amnesia, GI disturbances, upper and lower respiratory tract infection, fatigue, visual disturbances, increased ALT serum concentrations, abnormal LFT. Potentially Fatal: Hepatitis, anaphylactic reactions, angioedema, sleep-driving (driving while not fully awake after drug intake, w/ no recollection of the event).
Pregnancy category ::
Drug Mode of Action ::
Zolpidem is an imidazopyridine derivative that acts by binding to the benzodiazepine (BZD) receptors of the GABA receptor complex resulting in neuronal hyperpolarisation, action potential inhibition, increased in chloride conductance and decreased in neuronal excitability. It has strong sedative action but only minimal anxiolytic, myorelaxant and anticonvulsant properties due to its selectivity for the BZ1-receptor over the BZ2-receptor. Zolpidem has a rapid onset but short duration of hypnotic action.
Drug Interactions ::
Flumazenil reverses the sedative/hypnotic effect of zolpidem. Increased depressant effects w/ CNS depressants (e.g. sedatives, antihistamines, alcohol). Additive effect on decreased alertness and psychomotor performance w/ imipramine and chlorpromazine. Increased plasma concentration w/ itraconazole, ketoconazole and other CYP3A4 inhibitors. May decrease plasma concentration w/ CYP3A4 inducers (e.g. carbamazepine). Reduced hypnotic effect w/ rifampicin. Potentially Fatal: Increased risk of prolonged sedation and respiratory depression w/ ritonavir.